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Abstract
Background: Previous studies have found inflammation, growth factors, and androgen signaling pathways all
contribute to sarcopenia. However, few studies simultaneously have investigated the association between these
potential risk factors and sarcopenia among older people. The aim of the study was to investigate whether elevated
levels of inflammatory cytokines combined with low levels of anabolic hormone have a synergy effect on muscle
strength and functional decline in older people.
Methods: We designed a cross-sectional study of 1,131 subjects aged 60 years and older. Concentrations of serum
C-reactive protein, insulin-like growth factor 1 and dehydroepiandrosteronesulphate were assessed using
chemiluminescent immunoassays. Handgrip strength was measured using a dynamometer, and physical
performance was assessed using a four-meter gait speed and Timed Up and Go test. We defined poor physical
performance as a 4-m gait speed <0.8 m/s or Timed Up and Go test ≥13.5 s.
Results: After adjustment for potential confounding factors, in multiple linear regression analysis, C-reactive protein
levels are inversely related to handgrip strength (P <0.01), and in multiple logistic regression analysis, C-reactive
protein levels are inversely related to poor physical performance (P for trend <0.05) in males, but not in females.
After combining three biomarkers, no significant results were observed between biomarker scores and muscle
strength or physical performance.
Conclusions: In older males, higher serum C-reactive protein levels, but not insulin-like growth factor 1 and
dehydroepiandrosteronesulphate levels, are independently related to lower muscle strength and poor physical
performance. In this study we did not observe that a combination of higher catabolic biomarkers and lower
anabolic biomarkers were better predictors for muscle strength and physical performance.
Background
Sarcopenia is a syndrome characterized by progressive
and generalized loss of skeletal muscle mass, muscle
strength and function [1]. Sarcopenia is an important
clinical problem that impacts millions of older adults,
and can lead to a multitude of adverse consequences,
such as frailty, disability, morbidity, mortality, and higher
fall risk [2–4].
Previous studies have found inflammation, growth fac-
tors, and androgen signaling pathways all contribute to
sarcopenia. An extensive literature has shown that higher
levels of inflammatory markers [5–9] and low levels of
anabolic hormones were respectively associated with
muscle strength and physical performance decline in older
people [10–12]. Maintenance of muscle mass depends on
the balance between protein synthesis and degradation,
which are mediated by anabolic and catabolic signaling
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pathways [13, 14]. For example, the insulin-like growth
factor 1 (IGF-1) pathway actives protein synthesis and
inhibits degradation, thereby controlling the balance
of muscle protein turnover; thus, a decline in hor-
mones including IGF-1 and dehydroepiandrosterone-
sulphate (DHEAS), may contribute to development of
sarcopenia [15–18]. Moreover, since serum levels of
proinflammatory cytokines including interleukin-6 (IL-6)
and tumor necrosis factor-alpha increase with age, proin-
flammatory pathway activation could contribute to muscle
degradation and decreased protein synthesis [19]. Based
on above, inflammation, growth factors, and androgen
signaling pathways all contribute to sarcopenia. However,
to date, few studies simultaneously have investigated the
association between these potential risk factors and sarco-
penia among older people. Whether elevated levels of
inflammatory cytokines combined with low levels of ana-
bolic hormone have a synergy effect on muscle strength
and physical performance decline in older persons has not
been explored. Therefore, we performed a cross-sectional
study to explore the effect of high levels of catabolic bio-
markers combined with low levels of anabolic biomarkers




Our study population comprised of subjects aged 60 years
and older living in the Hangu area of Tianjin City, one of
the major cities of China. Face-to-face questionnaires were
carried out by specially-trained interviewers.
Exclusion criteria were aimed to minimize confound-
ing effects on sarcopenia. The following subjects were
excluded: (1) who were younger than 60 years (n = 24);
(2) whose serum DHEAS concentrations had not been
measured (n = 112); (3) whose serum C-reactive protein
(CRP) concentrations had not been measured (n = 4); (4)
Subjects whose hand was injured and subjects who can-
not walk by themselves or by the assistance of others or
instruments were excluded (n = 8). In addition, there
were 193 subjects who have not measured the 4-m gait
speed. As a result of these exclusions, the final cross-
sectional study population for muscle strength and
TUGT analysis were composed of 1,131 subjects [age
68.95 ± 6.94 years (mean ± standard deviation, SD); males:
47.39 %], and for 4-m gait speed analysis was composed of
938 subjects. The protocol used here was approved by the
Institutional Review Board of Tianjin Medical University,
and participants provided informed consent for analysis of
their data.
Measurement of blood samples
Overnight fasting blood samples were collected the
next morning. Serum IGF-1, CRP, DHEAS levels were
determined using chemiluminescent immunoassay kits
(Snibe, Shenzhen, China) according to the manufac-
turer instructions. The detection limit of this assay is
0.13 ng/ml for CRP, 5.0 ng/ml for IGF-1, and 1 μg/dl
for DHEAS. Intra-assay coefficient of variation for
CRP, IGF-1 and DHEAS were 7.8, 6.4 and 8.2 % re-
spectively, and inter-assay coefficient of variation for
CRP, IGF-1 and DHEAS were 10.2, 12.1 and 11.3 %
respectively.
Muscle strength
Evidence indicates that handgrip strength is highly
correlated with mortality in older or pathological per-
sons [20, 21]. Therefore, handgrip strength was chosen
as an indicator of overall muscle strength [22]. Handgrip
strength was measured using a dynamometer (EH101;
CAMRY, Guangdong, China). Dynamometer width was
adjusted for optimal fit for each participant. Participants
were instructed to stand upright and with the dynamom-
eter beside but not against their body. Participants were
asked perform 2 maximum force trials for each hand
and the measurements were recorded in kilograms. The
maximum value attained during the four trials was used
as the final score.
Physical performance
Four-meter gait speed and Timed Up and Go test
(TUGT) are a widely used criterion in geriatric assess-
ment; we used these measurements in order to assess
physical performance [1]. Four-meter gait speed has
been shown to be associated with survival in older adults
[23], and has also been shown to reflect health and func-
tional status [24]. It has thus been recommended as a
potentially useful clinical indicator of wellbeing among
older adults [25].
TUGT
The subjects were seated in a free-standing padded arm-
chair and stand up without use of arms, walk at a com-
fortable and safe pace to a line on the floor three meters
away, turn and walk back to the chair and sit down again
[26]. Time was measured while they rise from an arm
chair until complete the series of functionally task.
The TUGT is recommended as a routine screening
test for falls in guidelines published by the American
Geriatric Society and the British Geriatric Society [27], a
score of ≥13.5 s is used as a cut-point to identify those
at increased risk of falls in the community setting [28].
Thus we considered a score of ≥13.5 s indicated a low
physical performance.
Four-meter gait speed
Gait speed is considered a simple indicator of health sta-
tus and of survival in older persons [29]. It can be used
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as a quick, safe, inexpensive and highly reliable instru-
ment implemented to assess the physical function [30].
Participants walk for a 4 m distance at usual pace from a
standing start [23]. Each one was allowed walk two trials,
and the average speed was used for analyses. A walking
speed at the cut-off point of 0.8 m/s has been recom-
mended as measurement of sarcopenia [1].
Assessment of other variables
We use a standardized, structured interview question-
naire to gather information about lifestyle factors and
comorbidities. Physical activity (PA) in the most recent
week was assessed using the short form of the Inter-
national Physical Activity Questionnaire (IPAQ). Meta-
bolic equivalent (MET) hours per week were calculated
using corresponding MET coefficients (3.3, 4.0 and 8.0,
respectively) according to the following formula [31]:
MET coefficient of activity × duration (hours) × frequency
(days). Total physical activity levels were assessed by com-
bining separate scores for different activities.
Anthropometric parameters (height and body weight)
were recorded for each participant using a standardized
protocol. Body mass index (BMI) was calculated as weight
(kg)/height (m2).
Statistical analysis
Study population characteristics according to sex are
reported as means (standard deviation) or median (inter-
quartile range) values for continuous variables and pro-
portions for categorical variables. Pearson’s simple
correlation coefficients (r) were calculated to evaluate
the correlation between log-transformed biomarker
(CRP, IGF-1 or DHEAS) concentration and age. Correl-
ation of CRP, DHEAS, and IGF-1 with one another was
also determined by simple Pearson’s correlation. To ex-
plore the association between handgrip strength and
serum biomarkers, multiple linear regression analysis
Table 1 The characteristics of the study populationa
All Males Females
Characteristic (n = 1131) (n = 536) (n = 595)
Age, years 69.0 (6.94) b 69.9 (7.18) 68.1 (6.62)
BMI, kg/m2 25.4 (3.57) 25.1 (3.09) 25.7 (3.94)
Grip, kg 26.5 (9.37) 32.4 (7.94) 20.4 (5.43)
TUGT, s 11.2 (4.67) 11.0 (4.75) 11.4 (4.60)
4-m gait speed, m/s 0.99 (0.21) (n = 938) 1.03 (0.22) (n = 428) 0.95 (0.19) (n = 510)
CRP, mg/L 1.11 (0.49, 3.00) c 0.93 (0.43, 2.50) 1.36 (0.55, 3.48)
IGF-1, ng/mL 97.5 (86.5, 105.9) 95.1 (86.7, 107.1) 93.8 (86.3, 104.6)
DHEAS, ug/dL 127.7 (77.6, 175.0) 162.7 (115.8, 197.1) 91.7 (61.0, 129.4)
Smoking, %
Current 32.1 39.2 25.6
Former 19.6 27.7 12.4
Never 48.3 33.1 62.0
Drinking, %
Current 28.3 52.4 6.50
Fomer 11.8 22.7 1.88
Never 59.9 24.9 91.6
PA, METs-h/week 23.1 (3.93, 76.7) 30.8 (1.40, 88.6) 23.1 (4.95, 69.3)
Depression symptoms, % 14.5 13.9 15.0
Fall, % 20.7 17.3 23.7
Hypertension, % 37.0 29.5 43.7
Diabetes, % 14.2 11.4 16.6
Cancer, % 1.95 1.30 2.52
CVD, % 20.7 14.0 26.7
Anemia, % 1.24 0.75 1.68
aBMI body mass index, TUGT timed up and go test, CRP C-reactive protein, IGF-1 Insulin-like growth factor-1, DHEAS dehydroepiandrosteronesulphate, PA physical
activity, CVD cardiovascular disease
bValues are expressed as mean (standard deviation) (all such values)
cValues are expressed as median (interquartile range) (all such values)
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and analysis of covariance (ANCOVA) were used simul-
taneously. The value of handgrip strength was used as
the dependent variable, and the serum biomarker con-
centration levels were used as the independent variables.
Multiple logistic regression analysis was used to examine
the relationships between the tertiles of biomarkers
(CRP, IGF-1 and DHEAS) and poor physical perform-
ance (TUGT ≥13.5 s or 4-m gait speed <0.8 m/s) after
adjustment for covariates. Odds ratio (OR) and 95 %
confidence interval (CI) were calculated. In order to in-
vestigated whether anabolic and catabolic biomarkers
impact handgrip strength and physical performance sim-
ultaneously, three serum biomarkers were divided into
tertiles: the lowest tertile of IGF-1 and DHEAS recorded
as 1, the middle tertile of IGF-1 and DHEAS recorded as
2, and the highest tertile of IGF-1 and DHEAS recorded
as 3; and the low tertile of CRP recorded as 3, the mid-
dle tertile of CRP recorded as 2, the high tertile of CRP
recorded as 1. Then, we created variable biomarker scores
(ranging from 3 to 9) that were computed as follows: bio-
marker scores = CRP score + IGF-1 score + DHEAS score.
Then, we examined the relationship between the bio-
marker scores categories and handgrip strength or poor
physical performance.
All statistical tests were two-tailed and a significant
difference was defined as P <0.05. All statistical analyses
Fig. 1 a-c. The Pearson’s simple correlation between biomarkers (C-reactive protein, insulin-like growth factor 1 and dehydroepiandrosteronesulphate)
and age according to gender; d-f. The Pearson’s simple correlation of three biomarkers (C-reactive protein, insulin-like growth factor 1 and
dehydroepiandrosteronesulphate) between each other
Meng et al. BMC Musculoskeletal Disorders  (2015) 16:202 Page 4 of 10
were performed using Statistical Analysis System version
9.3 (SAS Institute Inc., Cary, NC, USA).
Results
The study cohort included 1,131 subjects, with a mean ±
SD age of 69.0 ± 6.9. Of these, 47.4 % were males (Table 1).
Log-transformed CRP concentration increased with age in
males (r = 0.13, P <0.01), and although not statistically sig-
nificant, log-transformed CRP also correlated positively to
age in females (r = 0.08, P = 0.07). IGF-1 concentration
decreased with age both in males (r = −0.25, P <0.0001)
and in females (r = −0.27, P <0.0001). Likewise, DHEAS
concentration also decreased with age in both sexes
(r = −0.29, P <0.0001 in males; r = −0.13, P <0.001 in
females). In males, CRP, DHEAS, IGF-1 significantly cor-
related with one another (CRP and DHEAS: r = −0.15,
P <0.001; CRP and IGF-1: r = −0.11, P <0.05; DHEAS
and IGF-1: r = 0.10, P <0.05); however, in females,
only CRP and IGF-1 displayed a significant correlation
(r = −0.11, P <0.01) (Fig. 1).
Multiple linear regression analyses were performed to
confirm the relationship between biomarkers concentra-
tion and handgrip strength. Log-transformed CRP, IGF-1,
DHEAS levels correlated significantly with muscle strength
in males using model 1 and model 2 (Table 2). In model 3,
muscle strength distinctly showed a significant relationship
with log-transformed CRP [standard regression coeffi-
cient (SRC) = −0.11; P <0.01] in males but not in females
(SRC = −0.01; P = 0.76) after additionally adjusting for
age. There was no significant relationship between log-
transformed IGF-1 and muscle strength in either males
or females (SRC = 0.04; P = 0.30 and SRC = 0.00; P = 0.80
respectively) after adjusting for potential confounders.
Likewise, log-transformed DHEAS values were not a
significant determinant of muscle strength (SRC = 0.05;
P = 0.17 and SRC = 0.01; P = 0.71 in males and females
respectively).
Table 3. shows the crude and adjusted relationship be-
tween physical performance (TUGT and 4-m gait speed)
in males and females participants. In the final multivari-
ate models, the adjusted OR (95 % CI) for TUGT across
CRP tertiles were 1.00 (reference), 1.09 (0.5, 2.39),
and 2.7 (1.34, 5.66) (P for trend <0.01) in males. The
adjusted OR (95 % CI) for 4-m gait speed across CRP
tertiles were 1.00 (reference), 1.25 (0.55, 2.88), and 2.84
(1.33, 6.33) (P for trend <0.05) in males. However, signifi-
cant results of TUGT and 4-m gait speed across CRP ter-
tiles were not observed in females. The reason of the
association between CRP and muscle strength and phys-
ical performance was sex-specific is not clear. Gender dif-
ference may be related to the tendency of healthier life
styles (eg. the percentage of women smokers and current
drinkers is lower in women than in men) in females than
males. Significant results of TUGT and 4-m gait speed
across IGF-1 and DHEAS tertiles were not observed both
in males and females.
Figure 2 a. displays the relationship between bio-
marker scores and muscle strength. Covariance
analysis (ANCOVA) showed that in the final multi-
variate models, significance values were attenuated
and were not statistically significant (P for trend =
0.05 in males, P for trend = 0.93 in females). This
suggests that the association between muscle strength
and serum biomarkers score is likely acting through an
aging pathway.
Figure 2 b and cdisplay the adjusted relationship
between biomarker scores and TUGT/4-m gait speed.
However, significant results of TUGT and 4-m gait
speed across biomarker scores were not observed both in
males and females.
Discussion
This cross-sectional study was conducted to assess the
association between serum biomarker levels (CRP, IGF-1,
and DHEAS) and muscle strength, physical performance
(TUGT and 4-m gait speed) in older individuals. We find
that elevated serum CRP is independently related to
muscle strength and physical performance in males. In
this study, we did not observe that a combination of
higher catabolic biomarkers and lower anabolic bio-
markers were better predictors for muscle strength and
physical performance.
Table 2 The relationship between biomarkers and handgrip
strength: multiple linear regression analysisa
Handgrip strength
Males Females
β standard β P β standard β P
Model 1b
CRP −0.99 −0.17 <0.001 −0.20 −0.05 0.27
IGF-1 4.87 0.18 <0.001 2.44 0.14 <0.001
DHEAS 3.14 0.19 <0.001 0.90 0.09 <0.05
Model 2c
CRP −0.90 −0.15 <0.001 −0.20 −0.04 0.26
IGF-1 3.48 0.13 <0.01 2.01 0.11 <0.01
DHEAS 2.94 0.17 <0.001 0.77 0.08 0.06
Model 3d
CRP −0.61 −0.11 <0.01 −0.04 −0.01 0.76
IGF-1 1.08 0.04 0.30 −0.17 0.00 0.80
DHEAS 0.90 0.05 0.17 0.13 0.01 0.71
aCRP C-reactive protein, IGF-1 Insulin-like growth factor-1,
DHEAS dehydroepiandrosteronesulphate
bCrude
cAdjusted for body mass index, smoking status, drinking status, physical
activity and comorbidities of (hypertension, diabetes, cancer, cardiovascular
disease, and anemia)
dAdditionally adjusted for age
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Table 3 Adjusted relationships of tertiles of biomarkers to the TUGT and 4-m gait speeda
Tertiles of biomarkers (Males) Tertiles of biomarkers (Females)
Low Middle High Low Middle High
Tertiles of CRP (range: mg/L) 0.02-0.31 (n =178) 0.31-0.93 (n = 179) 0.93-3.86 (n = 179) p for trend b 0.01-0.42 (n = 198) 0.42-1.36 (n = 198) 1.36-4.74 (n = 199) p for trend
No. of TUGT≥ 13.5 s 15 16 39 - 28 29 35 -
Crude Ref 1.15 (0.55, 2.40) c 2.97 (1.6, 5.78) <0.001 Ref 0.97 (0.55, 1.70) 1.26 (0.74, 2.17) 0.59
Model 1 Ref 1.09 (0.51, 2.36) 2.58 (1.32, 5.23) <0.01 Ref 0.63 (0.32, 1.20) 0.92 (0.49, 1.71) 0.41
Model 2 Ref 1.11 (0.51, 2.44) 2.81 (1.41, 5.85) <0.01 Ref 0.61 (0.31, 1.17) 0.91 (0.49, 1.71) 0.36
Model 3 Ref 1.09 (0.50, 2.39) 2.7 (1.34, 5.66) <0.01 Ref 0.58 (0.29, 1.12) 0.86 (0.46, 1.62) 0.33
Tertiles of IGF-1 (range: ng/mL) 18.1-81.8 (n =178) 81.8-95.1 (n = 179) 95.1-112.9 (n = 179) 5.87-82.5 (n =198) 82.5-93.8 (n = 196) 93.8-109.9 (n = 201)
No. of TUGT≥ 13.5 s 26 20 24 - 41 19 32 -
Crude Ref 0.67 (0.35, 1.25) 0.88 (0.48, 1.59) 0.62 Ref 0.43 (0.24, 0.76) 0.72 (0.43, 1.19) 0.01
Model 1 Ref 0.86 (0.44, 1.66) 1.24 (0.65, 2.38) 0.62 Ref 0.65 (0.33, 1.23) 1.19 (0.64, 2.2) 0.14
Model 2 Ref 0.84 (0.42, 1.66) 1.29 (0.66, 2.53) 0.53 Ref 0.61 (0.31, 1.18) 1.19 (0.65, 2.22) 0.10
Model 3 Ref 0.85 (0.42, 1.72) 1.27 (0.65, 2.49) 0.60 Ref 0.60 (0.30, 1.17) 1.12 (0.60, 2.11) 0.14
Tertiles of DHEAS (range: ug/dL) 21.2-0.31 (n =178) 0.31-0.93 (n = 179) 0.93-3.86 (n = 179) 12.4-50.1 (n = 198) 50.1-91.7 (n = 198) 91.7-150.8 (n = 199)
No. of TUGT≥ 13.5 s 34 20 16 - 39 22 31 -
Crude Ref 0.54 (0.29, 0.97) 0.42 (0.22, 0.78) <0.05 Ref 0.54 (0.31, 0.94) 0.73 (0.43, 1.23) 0.06
Model 1 Ref 0.89 (0.46, 1.7) 0.75 (0.37, 1.48) 0.68 Ref 0.65 (0.34, 1.2) 1.09 (0.6, 1.98) 0.15
Model 2 Ref 0.88 (0.45, 1.69) 0.73 (0.36, 1.47) 0.64 Ref 0.64 (0.34, 1.2) 1.06 (0.58, 1.95) 0.15
Model 3 Ref 0.93 (0.47, 1.82) 0.73 (0.35, 1.47) 0.64 Ref 0.71 (0.37, 1.33) 1.09 (0.59, 2.01) 0.25
Tertiles of CRP (range: mg/L) 0.02-0.31 (n =146) 0.31-0.93 (n = 147) 0.93-3.86 (n = 135) 0.01-0.42 (n = 181) 0.42-1.36 (n = 165) 1.36-4.74 (n = 164)
No. of 4 m gait speed < 0.8 m/s 14 15 29 - 30 31 27 -
Crude Ref 1.09 (0.50, 2.37) 2.6 (1.33, 5.30) <0.01 Ref 1.08 (0.62, 1.89) 0.97 (0.55, 1.7) 0.82
Model 1 Ref 1.13 (0.51, 2.55) 2.43 (1.18, 5.19) <0.05 Ref 0.76 (0.40, 1.43) 0.77 (0.41, 1.44) 0.72
Model 2 Ref 1.26 (0.56, 2.89) 2.88 (1.36, 6.37) <0.05 Ref 0.74 (0.39, 1.39) 0.75 (0.4, 1.4) 0.65
Model 3 Ref 1.25 (0.55, 2.88) 2.84 (1.33, 6.33) <0.05 Ref 0.72 (0.37, 1.37) 0.72 (0.37, 1.37) 0.59
Tertiles of IGF-1 (range: ng/mL) 18.1-81.8 (n =124) 81.8-95.1 (n = 159) 95.1-112.9 (n = 145) 5.87-82.5 (n =153) 82.5-93.8 (n = 175) 93.8-109.9 (n = 182)
No. of 4 m gait speed < 0.8 m/s 19 18 21 - 29 22 37 -
Crude Ref 0.63 (0.31, 1.26) 0.9 (0.46, 1.75) 0.57 Ref 0.68 (0.37, 1.22) 1.05 (0.61, 1.82) 0.13
Model 1 Ref 0.73 (0.35, 1.52) 1.2 (0.59, 2.47) 0.49 Ref 0.88 (0.46, 1.70) 1.31 (0.70, 2.47) 0.24
Model 2 Ref 0.73 (0.34, 1.54) 1.23 (0.59, 2.59) 0.46 Ref 0.94 (0.48, 1.82) 1.36 (0.72, 2.6) 0.26














Table 3 Adjusted relationships of tertiles of biomarkers to the TUGT and 4-m gait speeda (Continued)
Tertiles of DHEAS (range: ug/dL) 21.2-0.31 (n =130) 0.31-0.93 (n = 142) 0.93-3.86 (n = 156) 12.4-50.1 (n = 166) 50.1-91.7 (n = 169) 91.7-150.8 (n = 175)
No. of 4 m gait speed < 0.8 m/s 24 19 15 - 39 21 28 -
Crude Ref 0.68 (0.35, 1.30) 0.47 (0.23, 0.94) 0.10 Ref 0.49 (0.27, 0.87) 0.6 (0.35, 1.04) <0.05
Model 1 Ref 0.98 (0.49, 1.98) 0.72 (0.34, 1.49) 0.62 Ref 0.64 (0.34, 1.19) 0.86 (0.47, 1.57) 0.26
Model 2 Ref 0.95 (0.46, 1.95) 0.7 (0.32, 1.47) 0.60 Ref 0.62 (0.33, 1.16) 0.81 (0.44, 1.49) 0.23
Model 3 Ref 1.01 (0.48, 2.09) 0.68 (0.31, 1.44) 0.52 Ref 0.74 (0.38, 1.41) 0.86 (0.46, 1.62) 0.52
Model 1: adjusted for age and BMI
Model 2: adjusted for age, BMI, smoking status, and drinking status
Model 3: adjusted for age, BMI, smoking status, drinking status, physical activity and family history of cardiovascular disease, hypertension, diabetes, and cancer
aBMI body mass index, TUGT timed up and go test, CRP C-reactive protein, IGF-1 Insulin-like growth factor-1, DHEAS dehydroepiandrosteronesulphate
bAnalysis by multiple logistic regression analysis














These findings partially agree with several previous
studies that showed a significant association between
high C-reactive protein levels and the decline of physical
activity [32] or muscle strength [33] in older adults. In
our study, significant relationship between high CRP
levels and lower muscle strength and physical perform-
ance remained even when we adjusted for a number of
potential confounders. Whether or not CRP directly
affects skeletal muscle function is unknown; however,
results of experimental studies [34] support a direct link
between inflammatory markers and muscle mass. The
inverse relationship between serum CRP levels and
muscle strength and physical performance demonstrated
in this study is most likely explained by the catabolic effect
of inflammatory markers on muscle tissue. Increased circu-
lating levels of cytokines are associated with a progressive
increase in glucocorticoid and catecholamine levels and
suppression of the IGF1-Akt [also known as protein kinase
B (PKB)] pathway [35]. Nuclear factor-κB (NFκB) tran-
scription factors, which play major roles as mediators of
immunity and inflammation, are expressed in skeletal
muscle, where they mediate the effect of inflammatory cy-
tokines on muscle wasting and cachexia. Pro-inflammatory
cytokines are potent stimulants of proteolysis through the
NFκB signaling pathway [36].
Aging is associated with a variable decline of several
hormones, especially sex hormones (e.g. testosterone and
DHEAS) and growth hormones (e.g. growth hormone and
IGF-1) [37]. IGF-1 is a potent anabolic hormone mediat-
ing muscle growth and regeneration [38]. Experimental
studies have shown that systemic IGF-1 administration
increases the rate of skeletal muscle functional recovery
Fig. 2 The relationship between biomarker scores and muscle strength and physical performance. a The adjusted relationship between
biomarker scores and muscle strength. b The adjusted relationship between biomarker scores and TUGT. c The adjusted relationship between
biomarker scores and 4-meter gait speed
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after injury [39]. DHEAS is a major androgen in circula-
tion that is secreted by adrenal cortex [40]. The fact that
DHEAS levels decrease with age, means that it likely plays
an important role in age-related onset of sarcopenia.
DHEAS may induce beneficial age-related effects on body
composition and physical performance.
Although hormone status has an important relation-
ship with strength in older adults, our study failed to
find a positive relationship between serum IGF-1 or
DHEAS levels and muscle strength or physical perform-
ance after adjusting for potential confounders. In multi-
variate linear regression analysis, there is a significant
association between IGF-1, DHEAS and muscle strength
using model 1 (adjust for BMI, smoking status, alcohol
use, and PA) and model 2 (additionally adjusted for
comorbidities) both in males and females. However,
results produced using model 3 (additionally adjust for
age), were not significant. The similar results were also
observed in TUGT and 4-m gait speed using multiple
logistic regression analysis. These data suggest that
positive relationship between anabolic biomarkers and
muscle strength or physical function in older adults may
be mediated by age.
The major advantage of our study was using a com-
bination of catabolic and anabolic markers to evaluate
the relationship between biomarkers concentration and
muscle strength or physical performance. We found that
inflammation, growth factor, and androgen signaling
factors simultaneously related to aging, and also sig-
nificantly correlated with one other. In our study, we
demonstrated that higher catabolic biomarker levels
were related to lower muscle strength, and we did
not find that lower anabolic biomarkers (IGF-1 or
DHEAS) were related to decreased muscle strength.
One explanation for this may be age, which likely
contributes to the relationship between anabolic bio-
markers and muscle strength or physical function.
Another explanation may be that, although we used a
well-extablished standard measurement, the handgrip
strength test may not be sensitive enough to capture
true maximal strength. Moreover, after combining tertiled
biomarkers, we did not find any significant associations
between biomarker scores and muscle strength or physical
performance, suggesting that the impact of anabolic bio-
markers on muscle function are trivial and might attenu-
ate the relationship between catabolic biomarkers and
muscle strength or physical performance.
Limitations of this study include the fact that it was
cross-sectional; therefore, we cannot draw causative
conclusions about relationships between muscle strength
or physical performance and biomarkers. Moreover,
although in this study we demonstrated that there are
significant association of inflammation (as indexed by CRP)
with muscle strength and physical performance, other
inflammation factors such as IL-6 and TNF-a were not
measured. Although we adjusted for several confounders,
other unmeasured factors might have affected the
association between grip strength and inflammatory
markers. It is possible that elevated CRP levels reflect sub-
clinical disease processes that might be the cause of
muscle strength loss [5]. We were also unable to account
for severity of disease.
Conclusion
In conclusion, a higher serum CRP concentration is
independently related to lower muscle strength and
physical performance in older males. Considering that
the muscle strength and physical performance are parts
of the components of sarcopenia, and the health conse-
quences of sarcopenia are increasingly being recognized.
These results suggest that maintaining lower serum
levels of catabolic biomarkers like CRP may contribute
to higher muscle strength and improvement of adverse
sarcopenia-related outcomes. Additional well-designed
clinical studies or prospective interventional studies are
necessary to confirm these findings.
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